Servier has nine glioma abstracts for SNO 2026, but can the data expand its treatment reach?
Servier reveals its SNO 2026 plans for Voranigo and Ojemda, with long-term glioma outcomes, treatment durability and potential expansion in focus.
Pharma & Biotech
Pharma & Biotech
Is Nuvation Bio building the next IDH1 glioma contender with safusidenib and SIGMA?
Nuvation Bio now controls safusidenib globally. Read why the Japan deal matters for IDH1-mutant glioma, SIGMA, and the post-vorasidenib market.